Breakthrough Bio

Breakthrough Bio helps biotech and medtech companies enter the US market. Each company gets a commercialisation plan tailored to its stage and technology, with one-to-one support, regulatory guidance, investor relationships and industry connections. A flagship part of the programme prepares companies to turn the LSI USA and BIO International conferences into relationships and deals.

It is open only to companies headquartered in Israel or Taiwan. The Israel cohort is open only to companies incorporated and operating in Israel, and the Taiwan cohort only to companies headquartered in Taiwan. Companies headquartered elsewhere are not eligible.

What you get

• Access to US investors, healthcare leaders, regulatory experts and business development partners
• No participation fee. Selected companies pay their own US travel costs for three in-person immersions.

Who can apply

• Biotech companies working on therapeutic development
• Medtech companies working on devices, diagnostics, imaging, wearables and similar products
• AI drug discovery platforms, Taiwan cohort only

How to apply: Choose your country cohort on the programme page for eligibility and key dates. Applications for the Taiwan cohort opened on September 1, 2026, and the page shows them as open. The Israel cohort closed on August 24, 2026.